1. HBW Insight
  2. >>Health
  3. >>Business
  4. >>Deals

Perrigo Continues Overhaul Adding HRA Pharma, Boosts Chances For OTC Oral Contraceptive In US

 
• By Malcolm Spicer

HRA’s approval for pharmacy sales of a daily oral contraceptive the UK and its ongoing work on an NDA to propose making another progestin-only contraceptive ingredient available OTC in the US stand out as additions to Perrigo’s business with the most substantial revenue impacts.

• Source: Alamy

Pharma industry weight behind making daily oral contraceptives available OTC in the US gains substantial heft with Perrigo Company PLC’s planned acquisition of French firm HRA Pharma, which recently received UK approval for nonprescription sales of a daily-use progestin-only contraceptive.

With its acquisition of HRA, officially identified in France as Héra SAS, for €1.8bn ($2.1bn) in a cash deal announced...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Navamedic To Market OTC Naloxone In Norway Following Switch

 
• By Tom Gallen

Navamedic adds Ventizolve to its portfolio shortly after Norway switched the opioid overdose reversal drug from Rx to OTC.

Reckitt Strikes Deal To Sell Essential Home Unit To Focus On CHC, Hygiene

 
• By Tom Gallen

Advent International is poised to take control of Reckitt's Essential Home business, but the UK-based firm will retain a 30% stake.

Perrigo Implements Streamlining Plan With Sale Of Dermacosmetics

 
• By Tom Gallen

Perrigo stands to gain up to €327m with sale of brands such as ACO and Emolium to KKR.

Haleon Takes Full Control Of China JV

 
• By Tom Gallen

Haleon finalizes deal to make its China joint venture a wholly-owned subsidiary in move to "drive category growth in one of the fastest growing OTC markets globally."

More from Business

Navamedic To Market OTC Naloxone In Norway Following Switch

 
• By Tom Gallen

Navamedic adds Ventizolve to its portfolio shortly after Norway switched the opioid overdose reversal drug from Rx to OTC.

Green Regulation Is ‘A Baseline Not A Burden’ – Behind Opella’s B Corp Journey

 
• By David Ridley

“For us, regulation is the floor, not the ceiling,” Opella's chief sustainability officer Marissa Saretsky tells HBW Insight as the firm gains B Corp Certification. Other topics covered in this exclusive interview include Opella's position on the revised Urban Wastewater Treatment Directive.

Reckitt Strikes Deal To Sell Essential Home Unit To Focus On CHC, Hygiene

 
• By Tom Gallen

Advent International is poised to take control of Reckitt's Essential Home business, but the UK-based firm will retain a 30% stake.